BlackRock’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-38,735
| Closed | -$27.1K | – | 5468 |
|
|
2023
Q4 | $27.1K | Sell |
38,735
-795
| -2% | -$461 | ﹤0.01% | 5047 |
|
|
2023
Q3 | $27.2K | Hold |
39,530
| – | – | ﹤0.01% | 5099 |
|
|
2023
Q2 | $95.3K | Buy |
39,530
+2
| +0% | +$9 | ﹤0.01% | 4931 |
|
|
2023
Q1 | $321K | Sell |
39,528
-12
| -0% | -$159 | ﹤0.01% | 4654 |
|
|
2022
Q4 | $469K | Sell |
39,540
-16
| -0% | -$183 | ﹤0.01% | 4619 |
|
|
2022
Q3 | $549K | Sell |
39,556
-259
| -0.7% | -$6.68K | ﹤0.01% | 4698 |
|
|
2022
Q2 | $1.4M | Buy |
39,815
+73
| +0.2% | +$2.28K | ﹤0.01% | 4393 |
|
|
2022
Q1 | $1.59M | Buy |
39,742
+387
| +1% | +$16.6K | ﹤0.01% | 4489 |
|
|
2021
Q4 | $1.67M | Buy |
39,355
+149
| +0.4% | +$9.29K | ﹤0.01% | 4481 |
|
|
2021
Q3 | $2.66M | Buy |
39,206
+27
| +0.1% | +$1.98K | ﹤0.01% | 4199 |
|
|
2021
Q2 | $3.02M | Buy |
39,179
+12,203
| +45% | +$743K | ﹤0.01% | 4093 |
|
|
2021
Q1 | $1.77M | Buy |
26,976
+7,925
| +42% | +$617K | ﹤0.01% | 4321 |
|
|
2020
Q4 | $647K | Buy |
19,051
+4
| +0% | +$178 | ﹤0.01% | 4305 |
|
|
2020
Q3 | $1.04M | Hold |
19,047
| – | – | ﹤0.01% | 4102 |
|
|
2020
Q2 | $716K | Sell |
19,047
-2,121
| -10% | -$72.5K | ﹤0.01% | 4133 |
|
|
2020
Q1 | $530K | Buy |
21,168
+290
| +1% | +$12.3K | ﹤0.01% | 4041 |
|
|
2019
Q4 | $1.02M | Buy |
20,878
+7,221
| +53% | +$350K | ﹤0.01% | 3991 |
|
|
2019
Q3 | $674K | Sell |
13,657
-96
| -0.7% | -$6.9K | ﹤0.01% | 4097 |
|
|
2019
Q2 | $1.25M | Buy |
13,753
+205
| +2% | +$24.9K | ﹤0.01% | 3946 |
|
|
2019
Q1 | $2M | Sell |
13,548
-221
| -2% | -$42.7K | ﹤0.01% | 3706 |
|
|
2018
Q4 | $2.17M | Buy |
13,769
+1,063
| +8% | +$204K | ﹤0.01% | 3637 |
|
|
2018
Q3 | $3.11M | Buy |
12,706
+8,516
| +203% | +$2.02M | ﹤0.01% | 3637 |
|
|
2018
Q2 | $939K | Buy |
4,190
+298
| +8% | +$79.8K | ﹤0.01% | 3934 |
|
|
2018
Q1 | $954K | Sell |
3,892
-68
| -2% | -$17.8K | ﹤0.01% | 3894 |
|
|
2017
Q4 | $1.22M | Buy |
3,960
+99
| +3% | +$32.6K | ﹤0.01% | 3840 |
|
|
2017
Q3 | $1.41M | Sell |
3,861
-45
| -1% | -$16K | ﹤0.01% | 3799 |
|
|
2017
Q2 | $1.42M | Buy |
3,906
+1,066
| +38% | +$319K | ﹤0.01% | 3763 |
|
|
2017
Q1 | $844K | Buy |
+2,840
| New | +$717K | ﹤0.01% | 3848 |
|
Other funds holding DMK
BlackRock's DMK Position: Q1 2024 in Review
BlackRock sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q1 2024, closing a stake of 38,735 shares — an estimated $27.1K sold.
BlackRock first reported a position in DMK in Q1 2017 and held it in 28 quarters. The position peaked at $3.11M in Q3 2018. 3 funds tracked by Wall St. Rank hold DMK as of Q1 2024.
- BlackRock reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q1 2024 after selling out during the quarter.
- BlackRock sold 38,735 DMK Pharmaceuticals Corporation Common Stock shares in Q1 2024, an estimated $27.1K.
- BlackRock first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2017 and held it in 28 quarters.
- BlackRock's DMK Pharmaceuticals Corporation Common Stock position peaked at $3.11M in Q3 2018.
- 3 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q1 2024.
Based on BlackRock's 13F filing for Q1 2024, filed 10 May 2024.